Federal Register #2026-11926

NIA Seeks Licensees and Co-Development Partners for Fluorophthalimide Anti-Inflammatory Therapeutics

This opportunity is issued by the National Institute on Aging (NIA), part of the National Institutes of Health (NIH) under the Department of Health and Human Services (HHS). - The NIA is seeking research co-development partners and/or licensees for government-owned inventions involving fluorophthalimide compounds. - These compounds are novel thalidomide analogs developed as anti-inflammatory therapeutics. - Two distinct families of compounds are highlighted: - Fluorophthalimides with potent anti-inflammatory actions and reduced teratogenic risk - 4-amino-2-(piperidin-3-yl)isoindoline-1,3-diones with enhanced solubility, stability, and safety profile - The referenced technologies include NIH Reference Numbers E1512022 and E1832024, with related technologies E04520120 and E20820150. - Patent applications are pending for these inventions. - The compounds are intended for pre-clinical and clinical development, targeting therapeutic areas such as: - Neurology - Oncology - Geriatrics - Autoimmune disorders - No specific OEMs or commercial vendors are named, as the inventions are government-owned and available for licensing and collaborative research. - The opportunity is open to organizations interested in licensing or collaborative research for further development and commercialization.

Description

The National Institute on Aging (NIA) seeks research co-development partners and/or licensees for the pre-clinical and clinical development of fluorophthalimide compounds as anti-inflammatory therapeutics. These compounds target systemic and neurodegenerative disorders, aiming to provide safer and more potent alternatives to existing treatments. The technology involves novel thalidomide analogs that inhibit inflammation without the teratogenic effects associated with classic immunomodulatory imide drugs (IMiDs). Potential applications include treatment of neurodegenerative diseases, inflammatory disorders, autoimmune diseases, viral infections, and cancer.

View original listing